Back to search results

Study of 2-hydroxybenzylamine for Salt-Sensitive High Blood Pressure

This study is looking at how a drug called 2-hydroxybenzylamine (2-HOBA) affects people with salt-sensitive high blood pressure. This is a condition where your blood pressure goes up significantly when you eat salt. Researchers want to see if 2-HOBA can help lower blood pressure and reduce inflammation in these individuals. You might be able to join if you are an adult (18 or older) and have been previously identified as having salt-sensitive high blood pressure. The main goal is to see if 2-HOBA changes your 24-hour blood pressure readings over 4 to 12 weeks. The current status of this study is unclear, and it plans to enroll 20 participants.

Study design
This is a randomized, double-blind, placebo-controlled study involving 20 participants. It uses a crossover design where participants receive both 2-HOBA and a placebo at different times.
What's involved
You would take 2-HOBA or a placebo three times a day for 4 weeks, followed by a 4-week break, then the other treatment for 4 weeks. You will have assessments at weeks 0, 4, 8, and 12, and collect a 24-hour urine sample.
Compensation
Not stated in the trial record.
Follow-up
Your blood pressure will be monitored for 12 weeks during the study period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07602166

Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans

Not Yet Recruiting
PHASE2Ages 18+InterventionalTreatment
Vanderbilt University Medical Center
~20 participants
Updated 2026-07-28 on ClinicalTrials.gov
What's tested:2-hydroxybenzylaminePlacebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in 24-hour ambulatory systolic blood pressure (SBP)
Measured over From week 0-4 and week 8-week12

Conditions

Salt Sensitivity of Blood Pressure
High Blood Pressure
Inflammation
Renin-Angiotensin-Aldosterone System

Explore related trials

Autoimmune DiseaseCirrhosisHypertensionInfectionMalignant NeoplasmPsychiatric DisorderSalt Sensitivity of Blood PressureType 1 Diabetes MellitusType 2 Diabetes MellitusIsolevuglandins

Where it's being run

1 sites across 1 states
Tennessee1

Who to contact

Annet Kirabo, D.V.M., M.Sc., Ph.D. F.A.H.A.
[email protected]
615-343-0933
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

We will perform analyses in participants previously phenotyped for SSBP, defined as a change in systolic blood pressure ≥10 mmHg from salt-loading to salt-depletion,
Over 18 years of age. Able to give informed consent,
Concomitant diabetes mellitus, type I or II,
Autoimmune disease,
Recent vaccination,
Pregnant or breastfeeding
Women of childbearing potential unwilling to use highly effective contraceptive (see Risk section),
Confirmed or suspected renal, renovascular or endocrine causes of secondary hypertension,
Treatment with agents known to increase BP (e.g., adrenergic agonists for ADHD, SSRI and SNRI antidepressants, chronic use of decongestants or non-steroidal anti-inflammatory drugs,
Active or ongoing infection, including HIV/AIDS,
Active or ongoing malignancy with the exception of basal cell carcinoma of the skin,
Severe psychiatric disorders,
Any condition that may alter the immunological results of the study including rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, giant cell arteritis, psoriasis, inflammatory bowel disease, and multiple sclerosis,
Use of glucocorticoids, immunosuppressants, direct immunomodulators or chemotherapeutic drugs that in the judgment of the investigators may include a major inflammatory component,
Individuals who have contraindications to high salt diets (e.g. heart, renal, or liver failure) or low salt diets (e.g. postural orthostatic tachycardia syndrome, prescribed salt tablets, fludrocortisone or midodrine) or 24-hr ambulatory blood pressure monitoring (e.g. women with bilateral upper extremity lymphedema following breast cancer surgeries),
Prior diagnosis of liver cirrhosis or the following abnormal liver function studies: AST or ALT \>1.5x the upper limit of normal or total bilirubin ≥1.5 mg/dl,
Use of Aspirin,
Use of monoamine oxidase inhibitors (MAO-I),
Individuals with medical contraindications to certain food content,
Use of nitrate therapy. (Participants who are taking PDE-5 inhibitors will be instructed to discontinue use at least 48 hours prior to testing),
Patients with resistant hypertension, defined as above-goal blood pressure despite the concurrent use of three antihypertensive drug classes at screening, will be excluded for safety reasons,
Average of three office-based blood pressure readings greater than 160 mmHg systolic or 100 mmHg diastolic will not be eligible for enrollment,
Use of drugs such as anticoagulants (e.g., warfarin), beta-blockers, antiarrhythmics, antidepressants/antipsychotics, and other medications primarily metabolized by CYP2C9, CYP2C19, and CYP2D6 that may cause drug-drug interaction.

Exclusion

Salt-resistant people,
Acute cardiovascular event(s) within the previous 6 months,
inability to understand the nature, scope, and possible consequences of the study or to participate in/comply with the protocol,
Current excessive alcohol or illicit drug use,

What this trial measures

  • Change in 24-hour ambulatory systolic blood pressure (SBP)From week 0-4 and week 8-week12

    Measurement of salt sensitivity of blood pressure before and after each treatment period (2-HOBA and placebo), using a standardized inpatient salt-loading and salt-depletion protocol.